Bharat Biotech said it has begun the phase 3 trials of its Covid-19 vaccine candidate, Covaxin, in India. The phase-3 clinical trials will involve 26,000 participants across 22 sites in the country. It is the largest clinical trial conducted for a COVID-19 vaccine in India. The trial has been registered with the clinical trials registry of India, and approved by the Drugs Controller General of India (DCGI). Covaxin phase-3 clinical trials in India: All you need to knowTrial volunteers will receive two intramuscular injections about 28 days apart.

Source: Mint November 17, 2020 01:07 UTC